# KRYSTAL-1 (NCT03785249)

> Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

No report yet. It can be ordered.

- Drugs tested: adagrasib; adagrasib plus cetuximab; adagrasib plus pembrolizumab
- Indication: advanced solid tumors with KRAS G12C mutation

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03785249
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Mirati Therapeutics Inc.
- Conditions: Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
- Interventions: MRTX849; Pembrolizumab; Cetuximab; Afatinib
- Enrollment: 731
- Primary outcome: Characterize the safety of MRTX849 in patients having advanced solid tumor malignancies with KRAS G12C mutation
- Primary outcome: Evaluate the pharmacokinetics of MRTX849
- Primary outcome: Evaluate clinical activity/efficacy of MRTX849

## Indexed commentary on KRYSTAL-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 59
- YouTube: 25
- Podcasts: 22

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=krystal-1-nct03785249

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03785249", "email": "<work email>"}; the inbox owner confirms by the emailed link.